Trial watch: IDO inhibitors in cancer therapy

Erika Vacchelli1,2,3,4,*, Fernando Aranda1,2,3,*, Alexander Eggermont1, Catherine Sautès-Fridman1,5,6, Eric Tartour7,8,9, Eugene P Kennedy10, Michael Platten11,12, Laurence Zitvogel1,13, Guido Kroemer1,2,3,9,14,*, and Lorenzo Galluzzi1,12,3,7,*,‡

1Gustave Roussy Cancer Campus; Villejuif, France; 2INSERM U1138; Paris, France; 3Equipe 11labellisée maincatabolized via the so-called “kynurenine pathway”, i.e.,

Indoleamine 2,3-dioxygenase 1 (IDO1) is the main enzyme that catalyzes the first, rate-limiting step of the so-called “kynurenine pathway”, i.e., the metabolic cascade that converts the essential amino acid L-tryptophan (Trp) into L-kynurenine (Kyn). IDO1, which is expressed constitutively by some tissues and in an inducible manner by specific subsets of antigen-presenting cells, has been shown to play a role in the establishment and maintenance of peripheral tolerance. At least in part, this reflects the capacity of IDO1 to restrict the microenvironmental availability of Trp to favor the accumulation of Kyn and some of its derivatives. Also, several neoplastic lesions express IDO1, providing them with a means to evade anticancer immunosurveillance. This consideration has driven the development of several IDO1 inhibitors, some of which (including 1-methyltryptophan) have nowadays entered clinical evaluation. In animal tumor models, the inhibition of IDO1 by chemical or genetic interventions is indeed associated with the (re)activation of therapeutically relevant anticancer immune responses. This said, several immunotherapeutic regimens exert robust clinical activity in spite of their ability to promote the expression of IDO1. Moreover, 1-methyltryptophan has recently been shown to exert IDO1-independent immunostimulatory effects. Here, we summarize the preclinical and clinical studies testing the antineoplastic activity of IDO1-targeting interventions.

Introduction

In mammalian cells, the amino acid L-tryptophan (Trp) is mainly catabolized via the so-called “kynurenine pathway”, i.e., the metabolic cascade that converts it into L-kynurenine (Kyn).1,2 The first, rate-limiting step of the kynurenine pathway can be catalyzed by three distinct enzymes, namely, indoleamine 2,3-dioxygenase 1 (IDO1), IDO2, and tryptophan 2,3-dioxygenase (TDO2).1-7 IDO1 is by far the best characterized of these enzymes as it was involved in the host response to microbial challenges as early as in the late 1970s.8-11 In particular, IDO1 was proposed to participate in the innate response to pathogens by virtue of its ability to deplete the inflammatory microenvironment of Trp, which is essential not only for most (if not all) eukaryotes, but also for several bacterial species.12 Several cell types including specific subsets of dendritic cells (DCs), macrophages and immature monocytes express increased levels of IDO1 in response to inflammatory cues such as interferon γ (IFNγ) or signal transducer and activator of transcription 3 (STAT3)-activatory stimuli.13-18 In 1998, Munn and colleagues demonstrated for the first time that IDO1 exerts immunosuppressive, rather than immunostimulatory, functions, as it prevents the rejection of allogenic fetuses by the maternal immune system.19 This cornerstone discovery initiated an intense wave of investigation aimed at characterizing the molecular and cellular circuits that underlie the immunomodulatory activity of IDO1.1,20 In spite of such an experimental effort, the precise mechanisms by which IDO1 exerts immunosuppressive functions remain to be elucidated. Along similar lines, further experiments are required to understand to which extent IDO2 and TDO2 contribute to Trp catabolism in vivo.21 Indeed, purified IDO2 exhibits enzymatic activity under specific experimental conditions, but it generally is 20–30-fold less active than IDO1.22 According to current models, IDO1 would limit innate and adaptive immune responses by two non-mutually exclusive mechanisms, i.e., by depleting immune effector cells of Trp,12,23 and by promoting the accumulation of Kyn and some of its derivatives, 3-hydroxykynurenine and 3-hydroxyanthranilic acid.24,25 A decrease in Trp availability (below 0.5–1 µM,
according to Munn and colleagues) promotes indeed the accumulation of uncharged tRNA species, resulting in a general control non-derepressible 2 (GCN2)-dependent block in protein synthesis that is often accompanied by cell cycle arrest and (in immune cells) irresponsiveness to immunological challenges. Along similar lines, Kyn, 3-hydroxykynurenine and 3-hydroxyanthanilic acid, which signal via the aryl hydrocarbon receptor (AHR), have been shown not only to exert cytostatic and cytotoxic effects on various immune effectors, including CD8^+ T lymphocytes, natural killer (NK) cells and invariant NKT cells, but also to inhibit Th17 cells and to promote the differentiation of naïve CD4^+ T cells into CD4^+CD25^+Foxp3^+ regulatory T cells (Tregs), as well as the tolerogenic activity of DCs. This said, some authors failed to observe a decrease in the proliferation rates of T lymphocytes even in culture media that were completely depleted of Trp. Moreover, while IDO1 may cause significant reductions in Trp availability in vitro, it remains to be demonstrated whether a similar effect occurs in vivo, where Trp concentrations are in the range of 50–100 μM. Indirect observation of such a phenomenon can be inferred from the lack of an effect of the supplementation of Trp in the culture medium on the proliferation of malignant cells implanted in syngeneic hosts. However, while in some cases elevated levels of IDO1 are associated with poor patient prognosis, this is not always the case. Thus, the expression of IDO1 in tumor biopsies positively correlated with disease-free survival in a cohort of hepatocellular carcinoma (HCC) patients. Moreover, the ability of peripheral blood mononuclear cells isolated from HCC patients to lyse HCC cell lines in vitro was directly proportional to IDO1 expression levels in the former. Along similar lines, not only the number of IDO1-expressing microvessels was found to inversely (rather than positively) correlate with the amount of proliferating cancer cells in samples from primary and metastatic renal cell carcinoma patients, but elevated levels of IDO1 in the neoplastic compartment were also associated with long-term patient survival. These observations indicate that IDO1 may not always support tumor growth by virtue of its immunosuppressive functions.

Since IDO1 is upregulated in response to several inflammatory cues, including IFNγ and CpG oligodeoxynucleotides (ODNs), IDO1 may indeed constitute a marker of a clinically relevant inflammatory or immune response, in thus far resembling other IFNγ-responsive molecules. Moreover, at least theoretically, the overexpression of IDO1 by neoplastic cells should have a direct negative outcome on tumor growth as a result of the GCN2-dependent phosphorylation of eukaryotic translation initiation factor 2A (eIF2A) and the consequent arrest in protein synthesis. Accordingly, the ability of IFNγ to mediate antineoplastic effects in vitro is more pronounced in IDO1-competent cancer cells than in their IDO1-incompetent counterparts, and it can be at least partially reversed by the supplementation of Trp in the culture medium. Furthermore, the proliferation of malignant cells implanted in syngeneic hosts appears to be limited when these cells are induced to upregulate IDO1. Taken together, these observations indicate that the impact of IDO1 expression by malignant, vascular or immune components of the neoplastic microenvironment on tumor growth is less clear than generally thought.

Interestingly, developing tumors appear to recruit abundant amounts of IDO1^+ DCs, which may engage in a mutually reinforcing circuit with Tregs that express cytotoxic T lymphocyte associated protein 4 (CTLA4). In this scenario, CTLA4 has been proposed to initiate a forkhead box O3 (FOXO3)-dependent signal transduction cascade resulting in the upregulation of IDO1 (in DCs), which in turn would activate Tregs via the GCN2 and AHR pathway. This signaling circuit may
be relevant for the establishment of an immunosuppressive microenvironment in human neoplasms. In line with this notion, the combined inhibition of IDO1, CTLA4, and CD274 (an immunosuppressive molecule best known as PD-L1) has recently been shown to mediate superior therapeutic effects against well-established gliomas, in mice. Moreover, elevated expression levels of IDO1 at baseline have been associated with improved clinical outcome in melanoma patients treated with the CTLA4-targeting antibody ipilimumab.

In this Trial Watch, we discuss preclinical and clinical findings about the inhibition of IDO1 as a strategy for the re(activation) of tumor-targeting immune responses, and summarize clinical trials recently initiated to test this therapeutic paradigm in cancer patients. As a note, no IDO1 inhibitor is currently approved for use in humans by the US Food and Drug Administration (FDA) or equivalent agencies worldwide.

Preclinical and Clinical Development of IDO1 Inhibitors for Cancer Therapy

During the last decade, 1-methyltryptophan, a competitive inhibitor of IDO1 (and IDO2) that exists as a mixture of chiral isoforms (i.e., 1-methyl-D-tryptophan and 1-methyl-L-tryptophan), and genetic interventions specifically targeting IDO1 have been shown to inhibit tumor growth in rodent tumor models, along with the (re)elicitation of an anticancer immune response. However, targeting IDO1 as a standalone therapeutic intervention often fail to cause tumor eradication and to prevent disease progression. Thus, IDO1-targeting agents have been investigated for their ability to improve the efficacy of multiple chemotherapeutics, and some combinatorial regimens of this type had promising results in preclinical scenarios. Relatively recently, these findings convinced some oncologists on the possibility to test the safety and therapeutic potential of 1-methyl-D-tryptophan (also known as indoximod and NLG8189), second-generation IDO1 inhibitors (such as the orally available agent INCBO24360 and NLG919), and IDO1-targeting vaccines in cancer patients. So far, the pharmacological profile of several other IDO1 inhibitors—including 1-methyl-L-tryptophan, methylihydroxydantoin tryptophan, brassinin and derivatives, annulin B and derivatives, exiguousine A and derivatives, as well as INCBO23843—appears to be suboptimal for clinical development.

The first-in-man Phase I clinical trial involving indoximod enrolled a total of 48 adults with refractory solid malignancies (NCT01195311). In this dose-escalation study, oral indoximod was well tolerated up to a dose of 2000 mg twice a day, major toxicities being Grade 1 fatigue (1 case) and Grade 2 hypophysisis (2 cases, in patients previously subjected to several immunotherapies). Moreover, of 7 evaluable patients who received 200 mg indoximod per day (10 were originally enrolled on this dose), 5 experienced objective responses or disease stabilization. Finally, Iversen and colleagues have recently reported the results of a Phase I clinical trial evaluating the safety and therapeutic profile of an IDO1-targeting, peptide-based vaccine (NCT01191216). In this Phase I clinical trial, indoximod was tested as a means to support the therapeutic profile of docetaxel (a microtubular poison currently approved by the US FDA for the treatment of various neoplasms). This study was conducted on 27 patients with metastatic solid tumors to determine the maximum tolerated dose of indoximod given in combination with docetaxel. Patients were assigned to receive 300, 600, 1000, 1200 and 2000 mg indoximod p.o. twice a day, in combination with either 60 or 75 mg/m^2 docetaxel every 3 weeks. The most common side effects were fatigue (58.6%), anemia (51.7%), hyperglycemia (48.3%), infection (44.8%), and nausea (41.4%). Out of 22 evaluable patients, 4 experienced partial responses and 9 disease stabilization. The authors recommended a dose of 1200 mg indoximod twice a day in combination with 75 mg/m^2 docetaxel every 3 weeks for testing in a Phase II study, which they initiated themselves on a cohort of metastatic breast carcinoma patients (NCT01792050).

Preliminary results are also available from 2 distinct clinical trials assessing the safety and efficacy of INCBO24360 in oncological indications (NCT01195311; NCT01604889). NCT01195311, which has been completed, was a Phase I, open-label, dose-escalation study to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of INCBO24360 in subjects with advanced malignancies. In this setting, 52 patients were enrolled to receive 50–700 mg INCBO24360 p.o. twice a day in 28-d cycles until disease progression or unacceptable toxicity. The most frequent Grade 3 or 4 side effects were abdominal pain, hypokalemia, and fatigue (9.6% each) and 2 dose-limiting toxicities were recorded. Significant reduction in the circulating Kyn/Trp ratio were observed in all patients, but there were no objective responses. Still, 15 patients achieved disease stabilization, lasting more than 112 d in 7 of them. In another setting, 7 patients were assigned to receive 300 mg INCBO24360 p.o. twice a day plus 3 mg/kg ipilimumab i.v. every 3 weeks, and enrollment was stopped when 5 patients developed clinically significant elevations of circulating alanine transaminase (after 30–76 days of treatment). Six out of 7 patients were evaluable at discontinuation and all exhibited disease stabilization. Of note, corticosteroids and treatment discontinuation were sufficient to resolve hepatic symptoms. A second cohort of eight patients receiving ipilimumab in combination with 25 mg INCBO24360 p.o. twice a day was enrolled. One of these subjects experienced dose-limiting hepatic toxicity (Grade 3 aspartate aminotransferase elevation), while immunological side effects were manageable with temporary treatment discontinuation. At first evaluation, the disease control rate was 75%, 3 patients achieved radiologically confirmed partial responses, and 3 patient experienced disease stabilization for 79, 148, and >127 d.
(NCT01219348). In this setting, 15 individuals with metastatic non-small cell lung carcinoma achieving disease stabilization upon standard-of-care chemotherapy received an IDO1-derived peptide s.c. in combination with the Toll-like receptor 7 (TLR7) agonist imiquimod. No severe side effects were recorded, 1 patient achieved a partial response one year after vaccination, and 6 patients experienced prolonged (>8.5 months) disease stabilization. Moreover, the overall survival of these individuals was significantly improved as compared to that of similar patients excluded from the study owing to HLA expression profile. A majority of subjects enrolled in the study also developed IDO1-specific CD8+ T cells and manifested significant reductions in the amounts of circulating Tregs as compared to baseline levels. Taken together, these data suggest that not only pharmacological agents, but also other means of targeting IDO1 may provide clinical benefits to cancer patients.

As per official sources (http://www.clinicaltrials.gov), 2 additional clinical trials have been initiated to investigate the safety and efficacy of IDO1 inhibitors in oncological indications but have been interrupted. In particular, NCT00739609, testing indoximod as a standalone therapeutic intervention in subjects with relapsed or refractory solid tumors, has been terminated owing to lack of accrual, while NCT01982487, assessing the ability of INCB024360 to boost the efficacy of a NY-ESO-1-targeting recombinant vaccine, has been withdrawn prior to enrollment, for undisclosed reasons.

**Ongoing Clinical Trials**

When this Trial Watch was being redacted (August 2014), official sources listed no less than 16 clinical trials launched to evaluate the safety and efficacy of IDO1-targeting interventions in cancer patients (source http://www.clinicaltrials.gov). Six of these trials involve indoximod (NCT01042535; NCT01560923; NCT01792050; NCT02052648; NCT02073123; NCT02077881), 8 INCB024360 (NCT01604889; NCT01685255; NCT01792050; NCT02052648; NCT02073123; NCT02077881), 1 NLG919 (NCT02048709), and 1 an IDO1-derived peptide (NCT02077114) (Table 1).

In particular, indoximod is being tested in combination with (1) docetaxel (NCT01792050, see above) or an experimental DC-based vaccine (NCT01042535), in subjects with metastatic breast carcinoma; (2) temozolomide (an alkylating agent currently employed against glioma, astrocytoma and melanoma), in patients with primary brain neoplasms (NCT02052648); (3) ipilimumab, in adults with metastatic melanoma (NCT02073123); (4) gemcitabine (an immunostimulatory nucleoside analog approved for the treatment of several carcinomas) and paclitaxel (a microtubular poison used against cancer), in patients with metastatic pancreatic cancer (NCT02077881); and (5) sipuleucel-T (also known as Provenge, the sole DC-based preparation currently approved by the US FDA for use in humans), in individuals with refractory metastatic prostate carcinoma (NCT01560923).

In addition, INCB024360 is being evaluated: (1) as a standalone therapeutic intervention, in subjects with myelodysplastic syndromes (NCT01822691) or women with tumors of the reproductive tract (NCT01685255; NCT02042430); (2) in combination with ipilimumab (NCT01604889, see above), or a mixture of MHC Class I-restricted peptides (NCT01961115), in patients with unresectable or advanced melanoma; (3) in association with the intraperitoneal delivery of haploidentical NK cells and interleukin-2 (NCT02118285) or a DC-targeted variant of NY-ESO-1 and a TLR3 agonist (NCT02166905), in women with reproductive tract cancers; and (4) in combination with a monoclonal antibody targeting the immunosuppressive receptor programmed cell death 1 (PD1CD1, best known as PD-1). In subjects with advanced solid tumors (NCT02178722).

Finally, the safety and preliminary efficacy of NLG919 employed as a standalone therapeutic intervention are being assessed in patients with advanced solid tumors (NCT02048709), while an IDO1-derived peptide is being tested in combination with either ipilimumab or vemurafenib (an FDA-approved inhibitor of mutant BRAF) in subjects with unresectable Stage III or IV melanoma (NCT02077114).

**Concluding Remarks**

Although 1-methyl-L-tryptophan inhibits IDO1 much more efficiently that its D counterpart in cell-free assays and in cell lines, the immunostimulatory potential of the latter in vivo is superior. This explains why indoximod is currently developed in the clinic and 1-methyl-L-tryptophan not. Moreover, it adds to an increasing amount of evidence indicating that indoximod exerts IDO1-independent immunostimulatory effects. For instance, several immunostimulatory agents including IFNγ, CpG ODN, and monoclonal antibodies specific for tumor necrosis factor receptor superfamily, member 9 (TNFRSF9, best known as 4-1BB or CD137) have been shown to mediate therapeutic effects in preclinical or clinical scenarios in spite of their ability to upregulate IDO1 expression. Nonetheless, indoximod loses its ability to suppress tumor growth in Ido1−/− mice. Taken together, these observations suggest that the anticancer activity of indoximod may rely on mechanisms other than the inhibition of the enzymatic activity of IDO1. In further support of this notion, indoximod has recently been shown to interfere with the transcription and translation of IDO1, and to inhibit Trp transporters of the plasma membrane.

Although our understanding of the biological effects of indoximod and other IDO1 inhibitors is incomplete, these molecules appear to mediate potent antineoplastic effects along with the re(activation) of anticancer immunosurveillance. Precisely determining to which extent these effects are on-target (i.e., they stem from the blockage of Trp catabolism) may allow for the development of novel agents that promote a therapeutically relevant tumor-targeting immune response but fail to provoke systemic metabolic disturbances.
as they inhibit IDO1 at the whole body level. In this setting, it would be very interesting to see whether the antineoplastic activity of indoximod is preserved in mice expressing a catalytically inactive variant of Ido1. The results of this and other experiments aimed at disentangling the complex signaling pathways and metabolic circuities controlled by IDO1 are urgently awaited.

Disclosure of Potential Conflicts of Interest

EPK operates as Vice President for Clinical and Medical Affairs for NewLink Genetics Co. (Ames, IA USA).

References

1. Lob S, Konigstorfer A, Rammensee HG, Opelz G, Terness P. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer 2009; 9:445-52; PMID:19461669; http://dx.doi.org/10.1038/nrc2639
2. Moffett JR, Namboodiri MA. Tryptophan and the immune response. Immunol Cell Biol 2008; 86: 247-65; PMID:18418598; http://dx.doi.org/10.1046/j.1440-1711.2003.doi-1.01177.x
3. Mehler AH, Knox WE. The conversion of tryptophan to kynurenine in liver. II. The enzymatic hydrolysis of formylkynurenine. J Biol Chem 1950; 187:431-38; PMID:258162
4. Knox WE, Mehler AH. The conversion of tryptophan to kynurenine in liver. I. The coupled tryptophan peroxidase-oxidase system forming formylkynurenine. J Biol Chem 1956; 187:419-30; PMID:14794728
5. Lob S, Konigstorfer A, Zieker D, Brucher BL, Rammensee HG, Opelz G, Terness P. IDO1 and IDO2 are expressed in human tumors: levor but not dextror-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 2009; 58:153-57; PMID:18418598; http://dx.doi.org/10.1007/s00262-008-0513-6
6. Men R, Duhadaway JR, Kamasani U, Laurz-Klitznlop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 2007; 67:7002-87; PMID:17671174; http://dx.doi.org/10.1158/0008-5472.CAN-07-1872
7. Thackray SJ, Mowat CG, Chapman SK. Exploring the mechanism of tryptophan 2,3-dioxygenase. Biochem Soc Trans 2008; 36:1120-29; PMID:19025108; http://dx.doi.org/10.1042/BST0361120
8. Hayashi O, Yoshida R. Specific induction of pulmonary indoleamine 2,3-dioxygenase by bacterial lipopolysaccharide. Ciba Found Symp 1978;199-203; PMID:258162
9. Yoshida R, Hayashi O. Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide. Proc Natl Acad Sci U S A 1978; 75:3998-4000; PMID:279015; http://dx.doi.org/10.1073/pnas.75.8.3998
10. Uruil A, Yoshida R, Kintamura H, Hayashi O. Induction of indoleamine 2,3-dioxygenase in alveolar interstitial cells of mouse lungs by bacterial lipopolysaccharide. J Biol Chem 1983; 258:6621-27; PMID:6343379
11. Pfefferkorn ER. Interferon gamma blocks the growth of Tousplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci U S A 1984; 81:908-12; PMID:6422465; http://dx.doi.org/10.1073/pnas.81.5.908
12. Munn DH, Shaltis C, Arwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189:1363-72; PMID:10224276; http://dx.doi.org/10.1084/jem.189.13.1363
13. Guillonneau C, Hill M, Huber FX, Chiffoleau E, Herve C, Li XL, Heslan M, Ural C, Tesson L, Meneux S et al. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J Clin Invest 2007; 119:2096-106; PMID:17404623; http://dx.doi.org/10.1172/JCI28801
14. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 2000; 164:3596-99; PMID:10725715; http://dx.doi.org/10.1042/JCI28801
15. Giannoni P, Pietra G, Travaini G, Quarto R, Shyti G, Benelli R, Ottaggio L, Mingari MC, Zupo S, Cutrana

Table 1. Ongoing clinical trials testing the clinical profile of IDO1 inhibitors in cancer patients

| Agent                  | Indications                  | Phase | Status | Notes                                      | Ref.                        |
|------------------------|------------------------------|-------|--------|--------------------------------------------|-----------------------------|
| Indoximod              | Brain neoplasms              | I/II  | Recruiting | Combined with temozolomide                | NCT02052648                |
|                        | Breast carcinoma             | I/II  | Recruiting | Combined with an experimental DC-based vaccine | NCT01042535                |
|                        | Melanoma                    | I/II  | Recruiting | Combined with docetaxel                   | NCT01792050                |
|                        | Pancreatic carcinoma        | I/II  | Not recruiting | Combined with ipilimumab                | NCT02073123                |
|                        | Prostate carcinoma          | II    | Recruiting | Combined with gemcitabine and paclitaxel | NCT02077881                |
|                        |                             |       |         | Combined with sipuleucel-T                 | NCT01560923                |
| INCB024360             | MDS                          | II    | Active, not recruiting | As single agent                | NCT01822691                |
|                        | Melanoma                    | I/II  | Recruiting | Combined with ipilimumab                | NCT01604889                |
|                        | Reproductive tract tumors   | n.a.  | Recruiting | Combined with the adoptive transfer of NK cells and IL-2 | NCT02118285                |
|                        | Solid tumors                | II    | Recruiting | Combined with a PD1D1-targeting monoclonal antibody | NCT02178722                |
| NLG919                 | Solid tumors                | I     | Recruiting | As single agent                | NCT02048709                |
| IDO1-derived peptide   | Melanoma                    | I     | Recruiting | Combined with ipilimumab or vemurafenib | NCT02077114                |

Abbreviations: DC, dendritic cell; IDO1, indoleamine 2,3-dioxygenase1; IL-2, interleukin-2; MDS, myelodysplastic syndrome; n.a., not available; NK, natural killer; PDCD1, programmed cell death 1; polyICLC, polyinosinic:polycytidylic acid, stabilized in poly-L-lysine and carboxymethylcellulose. *Based on clinical trials not completed, withdrawn, terminated or suspended at the day of submission (source http://www.clinicaltrials.gov).
G et al. Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages. Haematologica 2009; 94:1078-87; PMID:19745686; http://dx.doi.org/10.3324/haematol.2009.019405

16. Rani, Jordan MB, Divanovic S, Herbert DR. IFN-gamma-driven IDO production from macrophages protects IL-4/IL-12-deficient mice against lethal during Schistosoma mansoni infection. Am J Pathol 2012; 180:2001-08; PMID:22426339; http://dx.doi.org/10.2353/ajpath.2012.01.013

17. Pottula R, Poluektova L, Braun K, Clerici L, Heilmann D, He, Liu K, Bizarguy P, Hancock WW, Vin-

18. Munn DH, Zhou M, Attwood JT, Bondarev I, Con-19. Munn DH, Zhou M, Attwood JT, Bondarev I, Con-20. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood 2005; 106:2582-96; PMID:15961516; http://dx.doi.org/10.1182/blood.2005.10.20.2582

21. Ball HJ, Sanchez-Perez A, Weiser S, Austin CJ, Astel-22. Ball HJ, Sanchez-Perez A, Weiser S, Austin CJ, Astel-23. Uyttenhove C, Pilotte L, Theate I, Stroobant V, 24. Ball HJ, Sanchez-Perez A, Weiser S, Austin CJ, Astel-

25. Opitz CA, Litzenburger UM, Sahm F, Ott M, Triebel C, Zelany T, Varca C, Bier T, Jostadt L, Schenk D, Weller M et al. An endogenous tumour-26. Chen W, Liang X, Peterson AJ, Munn DH, Velardi A et al. Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood 2006; 107:2846-54; PMID:16339401; http://dx.doi.org/10.1182/blood-2005-10-407

27. Fallarino F, Grebner U, You S, McGrath BC, Cavender DR. Vaccara C, Orabona C, Bianchi R, Bella-28. Potula R, Poluektova L, Braun K, Clerici L, Heilmann D, He, Liu K, Bizarguy P, Hancock WW, Vin-

29. Opitz CA, Litzenburger UM, Sahm F, Ott M, Triebel C, Zelany T, Varca C, Bier T, Jostadt L, Schenk D, Weller M et al. An endogenous tumour-promoting ligand of the human ayl hydrocarbon receptor. Nature 2011; 478:197-203; PMID:21976023; http://dx.doi.org/10.1038/nature10491

30. Frumento G, Rondot R, Toniatti M, Damonte G, Ben-31. Della Chiesa M, Carlonamato S, Frumento G, Bal-32. Naito R, Ziegler S, Sorensen EC, Popow R, Arie-33. Molano A, Illarionov PA, Besra GS, Putterman C, 34. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM,35.Slotmann P, Ploegh HL, Choi JH, Blalock AL, Chao-36. Rani R, Jordan MB, Divanovic S, Herbert DR. IFN-37. Favre D, Mold J, Hunt PW, Kanwar B, Loke P,38. Romani L, Fallarino F, Orabona C, Stainless R, Jermiin LS, D’Angelo C, Zelante T, Vacca C, Bistoni F, Fioretti L, Seu L, Barbour JD, Lowe MM, Jayawardene A, Awe-39. Jenabian MA, Patel M, Kema I, Kanagaratham C, 40. Munn DH, Sharma MD, Bhan D, Chander P, Marshall J, Bauer F, Miu J, McQuillan JA, Stocker R, Jermiin LS, D’Angelo C, Zelante T, Vacca C, Bistoni F, Fioretti L, Seu L, Barbour JD, Lowe MM, Jayawardene A, Awe-41. Orabona C, Vaccara C, Bicciato S, Luchini A, Fallarino F, Grebner U, You S, McGrath BC, Cavender DR. Vaccara C, Orabona C, Bianchi R, Bella-42. Nguyen NT, Kimura A, Nakahama T, Chinen I, Masuda K, Nohara K, Fujii-Kuriyama Y, Kishimoto T. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci U S A 2010; 107:19961-66; PMID:21046155; http://dx.doi.org/10.1073/pnas.1014043

43. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, 44. Orabona C, Vaccara C, Longerini F, De Luca A, Montagnoli C, Molano A, Illarionov PA, Besra GS, Putterman C, 45. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, 46. Chen W, Liang X, Peterson AJ, Munn DH, Velardi A et al. Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood 2006; 107:2846-54; PMID:16339401; http://dx.doi.org/10.1182/blood-2005-10-407

47. Fallarino F, Grebner U, You S, McGrath BC, Cavender DR. Vaccara C, Orabona C, Bianchi R, Bella-48. Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-independent adaptive T regulatory cell regulatory function. J Immunol 2008; 181:5396-404; PMID:18832696; http://dx.doi.org/10.4049/jimmunol.181.8.5396

49. Munn DH, Sharan D, Chander P, Marshall J, Bauer K, Hansen A, Koni PA, Iwashima M, Munn DH. Cutting edge: induced indoleamine 2,3-dioxygenase expression in dendritic cell subsets suppress T cell clonal expansion. J Immunol 2003; 171:1652-55; PMID:12892462; http://dx.doi.org/10.4049/jimmunol.171.1.1652

50. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, 51. Fallarino F, Grebner U, You S, McGrath BC, Cavender DR. Vaccara C, Orabona C, Bianchi R, Bella-
catalobism in plasmacytoid dendritic cells. Int Immunol 2005; 17:1429-38; PMID:16172135; http://dx.doi.org/10.1093/intimm/dxh321

52. Fullarino F, Aselin-Patulc C, Vacca C, Bianchi R, Giarini S, Fisetron MC, Trinchieri G, Grohmann U, Puccetti P. Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J Immunol 2004; 173:3748-54; PMID:15345931; http://dx.doi.org/10.4049/jimmunol.173.6.3748

53. Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Aruma M, Bazar BR, Mellor AL, Munn DH. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Treg via indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117:2570-82; PMID:17710230; http://dx.doi.org/10.1172/JCI31911

54. Derle RJ, Janka, G., E., Xu Q, Burlington WJ. Dendritic type determines the mechanism of bystander suppression by adaptive T regulatory cells specific for the minor antigen HA-1. J Immunol 2007; 179:5443-51; PMID:17875878; http://dx.doi.org/10.4049/jimmunol.179.5.5443

55. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonissen SC, Mesina JJ, Chandler P, Koni PA, Mellor AL. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2007; 119:1341-54; PMID:17524595; http://dx.doi.org/10.1172/JCI302158

56. Conrad G, Gillert M. Plasmacytoid dendritic cells and regulatory T cells in the tumor microenvironment: a dangerous liaison. Oncoimmunology 2013; 2:e28887; PMID:23927878; http://dx.doi.org/10.4161/onci.23887

57. Sintari V, Fager J, Vas, BL, Way CL, Menener-Caust C, Caust C, Bendriss-Vermare N. Plasmacytoid dendritic cells deficient in IFNα/β production promote the activation of FOXP3 regulatory T cells and are associated with poor outcome in aggressive cancer patients. Oncoimmunology 2013; 2:e232338; PMID:23482834; http://dx.doi.org/10.4161/onci.23238

58. Sonowalla L, Vachelli E, Galjon A, Gajewski T, Eggermont A, Fridman WH, Santos-Fründ CF, Ma Y, Tarrand JJ, Groggel I, et al. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012; 1:1323-43; PMID:22343596; http://dx.doi.org/10.4161/onci.22009

59. Boccon-Gibod L, Hardy JP, Hardw A, Anderson SA, Dolan MJ, Fuchs D, Shearer GM. HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood 2007; 109:3591-59; PMID:17158233; http://dx.doi.org/10.1182/blood-2007-07-107373

60. Planes R, Brahraou E. HIV-1 Tat protein induces the production of IDO in human monocyte derived-dendritic cells through a direct mechanism: effect on T cells proliferation. PLoS One 2013; 8:e74551; PMID:24073321; http://dx.doi.org/10.1371/journal.pone.0074551

61. Manches O, Fernandez MV, Plumas J, Chaperot L, Eggermont A, Fridman WH, Sanpol L. Indoleamine 2,3-dioxygenase expression in colorectal cancer: role in tumor suppression. J Immunol 2003; 169:3453-60; http://dx.doi.org/10.4049/jimmunol.169.7.3453

62. Grant RS, Naif H, Thuruthyil SJ, Nasr N, Littlejohn D, Antolin EP, Baban B, Lee JR, Houghton M, Munn DH. Indoleamine 2,3-Dioxygenase is a prognostic factor in colorectal adenocarcinoma. J Clin Oncol 2012; 30:15450-53; PMID:22018551; http://dx.doi.org/10.1002/jjci.2011.513

63. Brandacher G, Perathoner A, Lachauer R, Schneeberger S, Obritsch P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006; 12:1144-51; PMID:16499067; http://dx.doi.org/10.1158/1078-0432.CCR-05-1966

64. Fan K, Wang H, Chen MS, Zhang HK, Weng DS, Zhou J, Huang W, Li JJ, Song HF, Xia JC. Expression and prognostic role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008; 134:1247-53; PMID:18436865; http://dx.doi.org/10.1007/s00432-008-0395-1

65. Iversen T, Weiler C, Schnepp PR, Munn DH. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. Oncoimmunology 2013; 2:e234483; PMID:23802883; http://dx.doi.org/10.4161/onci.23428

66. Berchon C, Fontenay M, Cern S, Brice I, Allorge D, Hennart B, Lhermitte M, Quenel B. Metabolites of indoleamine 2,3-dioxygenase catalysis are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification. Leuk Res 2013; 37:575-79; PMID:23453284; http://dx.doi.org/10.1016/j.leukres.2013.02.001

67. Yoshikawa T, Hara T, Tsunumi H, Goto N, Hoshi M, Katagawa J, Kanemura N, Kasahara S, Ito H, Takeura M, et al. Serum concentration of L-tryptophan predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Eur J Haematol 2010; 84:304-09; PMID:19955374; http://dx.doi.org/10.1111/j.1600-0609.2009.01393.x

68. Itohi T, Goto S, Tahara K, Tone S, Kawano K, Kitano S. Immunoregulatory role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma. J Gastroenterol Hepatol 2004; 19:319-26; PMID:14748880; http://dx.doi.org/10.1111/j.1440-1746.2003.03253.x

69. Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ, Munn DH. Cutting edge: CpG oligonucleotides induce splenic CD11b+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol 2005; 175:5601-05; PMID:16327046; http://dx.doi.org/10.4049/jimmunol.175.9.5601

70. Wingender G, Garbi N, Schumak B, Jungerkes F, Wingender S, Gouttefangeas C, Thomsen BM, Holm B et al. Long-lasting过后的 Th1 immunity in survivors of haematological malignancies: evidence of memory T-cell effector function. Clin Exp Immunol 2012; 168:328-37; PMID:22161020; http://dx.doi.org/10.1111/j.1365-2249.2012.04438.x

71. Munn DH et al. Prognostic
tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013; 73:128-38; PMID:23315914; http://dx.doi.org/10.1158/0008-5472.CAN-12-2606
88. Spranger S, Spranger C, Zyu Y, Williams J, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013; 5:208ra116; PMID:23986400; http://dx.doi.org/10.1126/scitranslmed.3006504
89. Kepp O, Menger L, Vacchelli E, Tartour E, Antonia SJ, Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 2002; 101:151-55; PMID:12200992; http://dx.doi.org/10.1002/ijc.10345
90. Hoffman RM. Tumor growth control with IDO-silencing Salomonna-letter. Cancer Res 2013; 73:4391; PMID:23826662; http://dx.doi.org/10.1158/0008-5472.CAN-12-2179
91. Manuel ER, Diamond DJ. A road less traveled paved by IDO silencing: harnessing the antitumor activity of neurophils. Oncoimmunology 2013; 2:e23322; PMID:23802075; http://dx.doi.org/10.4161/onci.23322
92. Jiang N, Zhou A, Lai Y, Dong X, Wang H, Zhang X, Jiang N, Navarro B, Ichim TE, Urquhart B et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer 2013; 132:967-77; PMID:22870662; http://dx.doi.org/10.1002/ijc.27710
93. Blache CA, Manuel ER, Kalitcheva TL, Wong AN, Ellenhorn JD, Blazier BR, Diamond DJ. Systemic delivery of Salomonna pythium transformed with IDO shRNA to suppress tumor growth. Cancer Research 2012; 72:6447-56; PMID:22809116; http://dx.doi.org/10.1158/0008-5472.CAN-12-0193
94. Wang D, Saga Y, Murakami H, Sato N, Norakha I, Fujiwara H, Takei Y, Munn DH. Indoleamine 2,3-dioxygenase inhibitors: a novel immune suppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy. Cancer Immunol Immunother 2008; 57:427-36; PMID:18191092
95. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendegast GC, Munn DH. Induction of indoleamine 2,3-dioxygenase in dendritic cells by sterrosters of 1-methyltryptophan through aryl hydrocarbon receptor responses. Cancer Res 2007; 67:792-801; PMID:17234791; http://dx.doi.org/10.1158/0008-5472.CAN-06-2925
96. Mautino MR, Jauparai FA, Waldo J, Kumar S, Adams J, Van Allen C, Marconinovic-Fleck A, Munn D, Vahanian NN. A phase 1/2 study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. J Clin Oncol 2013; 31:3083-93; http://dx.doi.org/10.1200/JCO.2012.45.8988
97. Giheby GT, Hamid O, Gangadhar TC, Lutzyk J, Oluizinski AJ, Gajewski T, Clemmowol R, Bosarge P, Zhao Y, Newton RC et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. J Clin Oncol 2014; 32:abst 3010
98. Banerjee T, DuHadaway J, Gaspari P, Suranto-Ward E, Munn DH, Mellor AL, Malachowskip W, Prendegast GC, Muller A. Induction and antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene 2008; 27:2851-57; PMID:18026137; http://dx.doi.org/10.1038/sj.onc.1210939
99. Gaspari P, Banerjee T, Malachowskip W, Muller AJ, Prendegast GC, DuHadaway J, Bennett S, Donovan AM. Structure-activity study of brassinins derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem 2006; 49:684-92; PMID:16420054; http://dx.doi.org/10.1021/jm0508888
100. Carr G, Chung MK, Mauk AG, Andersen RJ. Syntesis of indoleamine 2,3-dioxygenase inhibitory analogues of the sponge alkaloid exiguamine A. J Med Chem 2008; 51:2634-37; PMID:18393489; http://dx.doi.org/10.1021/jm070413h
101. Bratiosa HC, Vottero E, Patrick BO, Van Soest R, Matamah T, Mauk AG, Andersen RJ. Exiguamine A, an indoleamine 2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua. J Am Chem Soc 2006; 128:16046-47; PMID:17165752; http://dx.doi.org/10.1021/ja062711k
102. Kumar S, Jaller D, Patel B, LaLonde JM, DuHadaway J, Malachowskip W, Prendegast GC, Muller AJ, Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem 2008; 51:4968-77; PMID:18665584; http://dx.doi.org/10.1021/jm800512a
103. Perrone A, Vottero E, Rediguer M, Mauk AG, Andersen RJ. Indoleamine 2,3-dioxygenase inhibitors from the
